All In Biotech

Drug Trial Radar · NCT02951754

Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: Nov 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Feb 2002

Primary completion

Dec 2032

Study completion Dec 2032

Sponsor

Lead sponsor
Hospital de Clinicas de Porto AlegreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Federal University of Rio Grande do Sul; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination for the Improvement of Higher Education Personnel
First posted
Nov 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

  • Immediate-release MethylphenidateDrug

    Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Self-reported changes in severity of ADHD symptomsTime frame: 1yr

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.